Bendamustine for Relapsed and Refractory Hodgkin Lymphomas: Four Cases and a Review of the Literature

References (27)

1. 1 Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma [DOI]
2. 2 Development of potent monoclonal antibody auristatin conjugates for cancer therapy [DOI]
3. 3 cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity [DOI]
4. 4 Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment [DOI]
5. 5 Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents [DOI]
6. 6 The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape [DOI]
7. 7 Bendamustine: Rebirth of an Old Drug [DOI]
8. 8 The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma [DOI]
9. 9 Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma [DOI]
10. 10 Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma [DOI]
11. 11 How I treat relapsed and refractory Hodgkin lymphoma [DOI]
12. 12 Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center [DOI]
13. 13 Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience [DOI]
14. 14 Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials [DOI]
15. 15 MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival [DOI]
16. 16 Managing relapsed and refractory Hodgkin lymphoma [DOI]
17. 17 Efficacy and safety of bendamustine for the treatment of patients with recurring H odgkin lymphoma [DOI]
18. 18 Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block [DOI]
19. 19 Bendamustine Is Highly Active in Heavily Pre-Treated Relapsed and Refractory Hodgkin Lymphoma and Serves as a Bridge to Allogeneic Stem Cell Transplant. [DOI]
20. 20 The Role of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphoma [DOI]
21. 21 Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin [DOI]
22. 22 Efficacy of bendamustine as salvage treatment in an heavily pre-treated Hodgkin lymphoma [DOI]
23. 23 Targeted Therapy in Relapsed Classical Hodgkin Lymphoma [DOI]
24. 24 Bendamustine: new perspective for an old drug in lymphoproliferative disorders [DOI]
25. 25 Bendamustine HCl (TREANDATM) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01). [DOI]
26. 26 Brentuximab vedotin: the science of common sense [DOI]
27. 27 Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma [DOI]

Cited by 0

No indexed citations yet.

Related research

• Fusarium Infection after Allogeneic Stem Cell Transplantation with Prolonged Neutropenia — shares topic coverage
• What a Clinical Hematologist should Know about B Cells? — shares topic coverage
• Brentuximab Vedotin and Bendamustine Protocol in Hodgkin Lymphoma: Report of Two Cases in Abidjan, Côte d'Ivoire — shares topic coverage